Effect of sertindole on QTc interval in patients with schizophrenia

Basit Öğe Kaydı
dc.contributor.authorAtmaca, Murad
dc.contributor.authorYavuzkir, Mustafa
dc.contributor.authorMermi, Osman
dc.contributor.authorTopuz, Mehtap
dc.contributor.authorKanmaz, Ebru
dc.contributor.authorTezcan, Ertan
dc.date.accessioned2024-07-12T21:52:27Z
dc.date.available2024-07-12T21:52:27Z
dc.date.issued2008en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractSertindole has been marketed and offered daily clinical practice only for 9 months in our country, so no data has been its QTc prolongation potential. In the present study, we performed a clinical trial to investigate the effects of sertindole on QTc in patients with schizophrenia. The study comprised 21 patients with schizophrenia. Sertindole was administered in the following dosing regime: treatment was initiated with 4 mg/day sertindole. From day 3 to day 6, the dose was increased to 8 mg/day, and up to day 9, it was raised to 12 mg/day. The protocol allowed up to dose of 20 mg/day according to effectiveness and tolerability. QTc values were determined at beginning, months 3 and 6. In addition, Positive and Negative Syndrome Scale (PANSS) were scored concomitantly. At the beginning of 6-month period, the mean QTc interval of patients was 391.7 +/- 19.2 ms. At the end of this period, it was 402.8 +/- 23.8 ms. Although the mean QTc interval changing was significant throughout 6-month period, of the patients, at any evaluation point, only 1 female (451 ms) and 1 male (433 ms) had borderline prolongation at month 3 for both, without any exceeding the dangerous limits. In summary, our results suggest that sertindole is tolerable and despite dose-related QT prolongation, sertindole had not the proarrhythmic profile. Future studies with larger sample evaluating the effects of treatment are required. (c) 2008 Published by Elsevier Ireland Ltd.en_US
dc.identifier.doi10.1016/j.neulet.2008.05.065
dc.identifier.endpage3en_US
dc.identifier.issn0304-3940
dc.identifier.issue1en_US
dc.identifier.pmid18639380en_US
dc.identifier.scopus2-s2.0-47749151020en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.neulet.2008.05.065
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8378
dc.identifier.volume442en_US
dc.identifier.wosWOS:000258944600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherELSEVIER IRELAND LTDen_US
dc.relation.ispartofNEUROSCIENCE LETTERSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY03103
dc.subjectQTcen_US
dc.subjectprolongationen_US
dc.subjectsertindoleen_US
dc.subjectschizophreniaen_US
dc.titleEffect of sertindole on QTc interval in patients with schizophreniaen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu